Breaking News Instant updates and real-time market news.

NUPMF

New Pacific Metals

$0.00 /

+ (+0.00%)

07:58
08/10/20
08/10
07:58
08/10/20
07:58

New Pacific Metals graduates to TSX

New Pacific Metals is pleased to announce that it has received final approval for the listing of its common shares on the Toronto Stock Exchange. New Pacific's common shares will commence trading on the TSX effective as of market open on August 11, 2020 under the current trading symbol of "NUAG". In connection with the TSX listing, New Pacific's common shares will be voluntarily de-listed from the TSX Venture Exchange effective as of the commencement of trading on the TSX.

NUPMF New Pacific Metals
$0.00 /

+ (+0.00%)

06/26/20 BMO Capital
New Pacific Metals price target raised to C$5.50 from C$4.50 at BMO Capital
01/06/20 BMO Capital
New Pacific Metals downgraded to Market Perform from Outperform at BMO Capital
08/13/19 BMO Capital
New Pacific Metals initiated with an Outperform at BMO Capital

TODAY'S FREE FLY STORIES

General news
Asian Market Update: » 03:05
04/12/21
04/12
03:05
04/12/21
03:05
$ECON

Economic Data

/

+

Asian Market Update:…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
    General news
    Treasury budget preview » 03:05
    04/12/21
    04/12
    03:05
    04/12/21
    03:05
    $ECON

    Economic Data

    /

    +

    Treasury budget preview:…

    Story temporarily locked.
    To read stories as they happen please subscribe, Login above, or return in 9 minutes

    Get Free Trial

    ShowHide Related Items >><<
      General news
      Treasury auction outlook: the Treasury kicks off the $120 B in coupon offerings today » 03:05
      04/12/21
      04/12
      03:05
      04/12/21
      03:05
      $ECON

      Economic Data

      /

      +

      Treasury auction outlook:…

      Story temporarily locked.
      To read stories as they happen please subscribe, Login above, or return tomorrow

      Get Free Trial

      ShowHide Related Items >><<
        Initiation
        Sun Country Airlines initiated with a Buy at Goldman Sachs » 21:09
        04/11/21
        04/11
        21:09
        04/11/21
        21:09
        SNCY

        Sun Country Airlines

        $38.18 /

        -0.08 (-0.21%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Catherine O'Brien initiated coverage of Sun Country Airlines with a Buy rating and $45 price target, implying 18% upside potential from current levels. As an ultra-low cost carrier focused on serving primarily domestic, leisure passengers, Sun Country is well positioned to the "growing recovery" in air travel demand, O'Brien tells investors in a research note. U.S. demand has seen a material improvement in recent weeks, with the 7-day moving average down 38% versus 2019 on April 8 from down 56% at the end of February, almost exclusively driven by leisure demand, says the analyst. O'Brien believes the stock's valuation "remains supportive" despite the 59% increase in shares since the pricing of the initial public offering.

        ShowHide Related Items >><<
        • 17
          Mar
        SNCY Sun Country Airlines
        $38.18 /

        -0.08 (-0.21%)

        SNCY Sun Country Airlines
        $38.18 /

        -0.08 (-0.21%)

        Hot Stocks
        Hill-Rom reconfirms position that BardyDx deal closing conditions not met » 20:54
        04/11/21
        04/11
        20:54
        04/11/21
        20:54
        HRC

        Hill-Rom

        $112.89 /

        +1.6 (+1.44%)

        Hillrom previously…

        Hillrom previously announced its intent to acquire Bardy Diagnostics. On April 10, the Medicare Administrative Contractor, or MAC, Novitas Solutions, published updated reimbursement rates applicable to the Current Procedural Terminology, or CPT, codes 93241, 93243, 93245 and 93247 for the extended Holter cardiac monitoring category applicable to all of BardyDx's products and services. The original Novitas rate decision was published on January 29, 2021. Following the updated Novitas rate decision, Hillrom reconfirms its position that a "Company Material Adverse Effect" has occurred under the acquisition agreement with BardyDx, and therefore closing conditions have not been satisfied. "Hillrom will not comment further due to current litigation with BardyDx, which is pending in the Delaware Court of Chancery with trial scheduled to begin May 5, 2021. Hillrom remains committed to creating long-term shareholder value, and as previously disclosed will host its fiscal second quarter 2021 earnings conference call and webcast on Friday, April 30," the company stated.

        ShowHide Related Items >><<
        HRC Hill-Rom
        $112.89 /

        +1.6 (+1.44%)

        HRC Hill-Rom
        $112.89 /

        +1.6 (+1.44%)

        02/08/21 Baird
        Hill-Rom price target raised to $115 from $105 at Baird
        01/25/21 Morgan Stanley
        iRhythm price target raised to $288 from $227 at Morgan Stanley
        11/04/20
        Fly Intel: Top five analyst downgrades
        11/04/20
        Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
        HRC Hill-Rom
        $112.89 /

        +1.6 (+1.44%)

        Hot Stocks
        Fly Intel: Top five weekend stock stories » 20:05
        04/11/21
        04/11
        20:05
        04/11/21
        20:05
        MSFT

        Microsoft

        $255.73 /

        +2.37 (+0.94%)

        , NUAN

        Nuance

        $45.59 /

        +0.38 (+0.84%)

        , DSRLF

        DiaSorin SpA

        $165.82 /

        +0.8151 (+0.49%)

        , LMNX

        Luminex

        $32.92 /

        +0.64 (+1.98%)

        , AFRM

        Affirm

        $70.60 /

        +0.81 (+1.16%)

        , T

        AT&T

        $30.04 /

        +0.04 (+0.13%)

        , IIVI

        II-VI

        $76.26 /

        +0.04 (+0.05%)

        , GS

        Goldman Sachs

        $330.85 /

        -0.13 (-0.04%)

        , CCL

        Carnival

        $29.30 /

        +0.73 (+2.56%)

        , NCLH

        Norwegian Cruise Line

        $30.53 /

        -0.08 (-0.26%)

        , RCL

        Royal Caribbean

        $89.86 /

        +0.08 (+0.09%)

        , CS

        Credit Suisse

        $10.64 /

        -0.305 (-2.79%)

        Catch up on the…

        Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Microsoft (MSFT) is in advanced talks to buy Nuance Communications (NUAN) in a deal with an equity value of about $16B, or about $56 per share, reported Bloomberg's Liana Baker, Kiel Porter, and Dina Bass, citing people familiar with the matter. Microsoft and Nuance have collaborated since 2019, noted the report, which added that an agreement could be announced as soon as this week. 2. DiaSorin SpA (DSRLF) announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex (LMNX) for a price of $37 per share in an all-cash transaction. This corresponds to a total equity value of approximately $1.8B on a fully diluted basis and an enterprise value of approximately $1.8B. Following the acquisition, the combined entity will have combined 2020 revenues of approximately EUR 1.25B, adjusted EBITDA of approximately EUR 472M, and positive Net Financial Position of approximately EUR 335M. The transaction is expected to close within the third quarter of 2021 and is subject to Luminex shareholder approval and to other customary closing conditions, including the satisfaction of antitrust and CFIUS regulatory requirements. The transaction will be immediately accretive to DiaSorin's earnings per share following closing of the transaction and will generate an attractive return on invested capital profile. The combination is also anticipated to result in cost synergies of approximately $55M within 3 years after closing. 3. The next few months should be boom times for retailers as stimulus checks pump up the economy, but consumers aren't shopping the way they used to as they are souring on credit, and they are increasingly likely to shop online with a digital wallet rather than pull out cash in a store, Daren Fonda wrote in this week's edition of Barron's. The trends are fueling the "buy now, pay later," and they could lift the shares of Affirm Holdings (AFRM), added the author. 4. Legendary and AT&T (T) subsidiary Warner Bros.' "Godzilla vs. Kong" stayed number 1 in its second outing with an estimated $13.4M from 3,084 locations for a domestic cume of $69.5M and a global total of about $360M. The movie is expected to pass up "Tenet" at $365M worldwide sometime this week to rank as the top-grossing during this pandemic. 5. II-VI (IIVI) and Goldman Sachs (GS) saw positive mentions in this week's edition of Barron's, while Carnival (CCL), Norwegian Cruise Line Holdings (NCLH), Royal Caribbean Group (RCL), and Credit Suisse (CS) were mentioned cautiously.

        ShowHide Related Items >><<
        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        RCL Royal Caribbean
        $89.86 /

        +0.08 (+0.09%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        NCLH Norwegian Cruise Line
        $30.53 /

        -0.08 (-0.26%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        IIVI II-VI
        $76.26 /

        +0.04 (+0.05%)

        GS Goldman Sachs
        $330.85 /

        -0.13 (-0.04%)

        DSRLF DiaSorin SpA
        $165.82 /

        +0.8151 (+0.49%)

        CS Credit Suisse
        $10.64 /

        -0.305 (-2.79%)

        CCL Carnival
        $29.30 /

        +0.73 (+2.56%)

        AFRM Affirm
        $70.60 /

        +0.81 (+1.16%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        04/09/21 BTIG
        Okta upgraded to Buy from Neutral at BTIG
        04/08/21 Morgan Stanley
        CIO survey provides strong data points for Microsoft, says Morgan Stanley
        04/05/21
        Fly Intel: Top five analyst initiations
        04/05/21 Credit Suisse
        Microsoft assumed with an Outperform at Credit Suisse
        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        03/10/21 Wedbush
        Nuance added to Best Ideas List at Wedbush
        03/08/21 Morgan Stanley
        Software industry rating raised to Attractive from In-Line at Morgan Stanley
        02/09/21 Craig-Hallum
        Nuance price target raised to $58 from $41 at Craig-Hallum
        01/21/21 Barclays
        Nuance price target raised to $60 from $47 at Barclays
        DSRLF DiaSorin SpA
        $165.82 /

        +0.8151 (+0.49%)

        03/24/21 Berenberg
        DiaSorin SpA price target lowered to EUR 150 from EUR 180 at Berenberg
        03/18/21 Morgan Stanley
        DiaSorin SpA downgraded to Underweight from Equal Weight at Morgan Stanley
        12/10/20 Exane BNP Paribas
        DiaSorin SpA price target raised to EUR 145 from EUR 135 at Exane BNP Paribas
        12/10/20 Kepler Cheuvreux
        DiaSorin SpA upgraded to Buy from Hold at Kepler Cheuvreux
        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        02/18/21 Piper Sandler
        Luminex shares are undervalued, says Piper Sandler
        12/17/20 BTIG
        Illumina upgraded to Buy from Neutral at BTIG
        11/09/20 Piper Sandler
        Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
        11/06/20 Piper Sandler
        Luminex's new product launches can drive long-term growth, says Piper Sandler
        AFRM Affirm
        $70.60 /

        +0.81 (+1.16%)

        03/25/21 BofA
        Affirm initiated with a Neutral at BofA
        03/17/21 Wedbush
        LendingClub price target raised to $20.50 from $14 at Wedbush
        03/17/21 Deutsche Bank
        Affirm price target lowered to $92 from $120 at Deutsche Bank
        02/16/21 Barclays
        Affirm price target raised to $148 from $132 at Barclays
        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        03/10/21 RBC Capital
        Fortinet price target raised to $175 from $162 at RBC Capital
        03/10/21 DA Davidson
        Fortinet price target raised to $200 from $180 at DA Davidson
        03/10/21 BTIG
        Fortinet price target raised to $205 from $183 at BTIG
        03/05/21 JPMorgan
        JPMorgan sees AT&T rallying into analyst meeting, but not after
        IIVI II-VI
        $76.26 /

        +0.04 (+0.05%)

        03/30/21 Canaccord
        II-VI price target lowered to $125 from $152 at Canaccord
        03/26/21 Northland
        NeoPhotonics deal 'makes more sense than ever' for Lumentum, says Northland
        03/26/21 Cowen
        II-VI weakness on deal announcement a buying opportunity, says Cowen
        03/26/21 B. Riley
        II-VI upgraded to Buy from Neutral at B. Riley Securities
        GS Goldman Sachs
        $330.85 /

        -0.13 (-0.04%)

        04/09/21 JMP Securities
        Goldman Sachs price target raised to $400 from $338 at JMP Securities
        04/08/21 Citi
        Goldman Sachs price target raised to $390 from $370 at Citi
        04/07/21 Barclays
        Goldman Sachs price target raised to $420 from $392 at Barclays
        04/01/21
        Fly Intel: Top five analyst downgrades
        CCL Carnival
        $29.30 /

        +0.73 (+2.56%)

        04/09/21
        Fly Intel: Top five analyst upgrades
        04/09/21 Argus
        Carnival upgraded to Buy from Hold at Argus sees 'strong' pent-up cruise demand
        04/09/21 Argus
        Carnival upgraded to Buy from Hold at Argus
        04/09/21 Credit Suisse
        Carnival upgraded to Outperform from Neutral at Credit Suisse
        NCLH Norwegian Cruise Line
        $30.53 /

        -0.08 (-0.26%)

        03/24/21 Stifel
        Cruiseline stock selloff 'unwarranted,' says Stifel
        03/18/21 UBS
        Norwegian Cruise Line price target raised to $32 from $21 at UBS
        03/16/21 JPMorgan
        Norwegian Cruise Line price target raised to $36 from $33 at JPMorgan
        03/12/21 Truist
        Norwegian Cruise Line price target raised to $25 from $20 at Truist
        RCL Royal Caribbean
        $89.86 /

        +0.08 (+0.09%)

        03/18/21 UBS
        Royal Caribbean price target raised to $116 from $79 at UBS
        03/16/21 JPMorgan
        Royal Caribbean price target raised to $110 from $100 at JPMorgan
        03/12/21 Truist
        Royal Caribbean price target raised to $68 from $48 at Truist
        CS Credit Suisse
        $10.64 /

        -0.305 (-2.79%)

        04/09/21
        Fly Intel: Top five analyst downgrades
        04/09/21 Morgan Stanley
        Credit Suisse downgraded to Equal Weight from Overweight at Morgan Stanley
        04/07/21 RBC Capital
        Credit Suisse price target lowered to CHF 11 from CHF 14.50 at RBC Capital
        04/07/21 Exane BNP Paribas
        Credit Suisse downgraded to Neutral from Outperform at Exane BNP Paribas
        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        RCL Royal Caribbean
        $89.86 /

        +0.08 (+0.09%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        NCLH Norwegian Cruise Line
        $30.53 /

        -0.08 (-0.26%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        IIVI II-VI
        $76.26 /

        +0.04 (+0.05%)

        GS Goldman Sachs
        $330.85 /

        -0.13 (-0.04%)

        CS Credit Suisse
        $10.64 /

        -0.305 (-2.79%)

        CCL Carnival
        $29.30 /

        +0.73 (+2.56%)

        AFRM Affirm
        $70.60 /

        +0.81 (+1.16%)

        • 05
          Mar
        • 01
          Mar
        • 23
          Feb
        • 13
          Jan
        • 18
          Nov
        • 14
          Oct
        • 17
          Jul
        • 02
          Jul
        • 06
          May
        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        NCLH Norwegian Cruise Line
        $30.53 /

        -0.08 (-0.26%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        IIVI II-VI
        $76.26 /

        +0.04 (+0.05%)

        GS Goldman Sachs
        $330.85 /

        -0.13 (-0.04%)

        DSRLF DiaSorin SpA
        $165.82 /

        +0.8151 (+0.49%)

        CS Credit Suisse
        $10.64 /

        -0.305 (-2.79%)

        CCL Carnival
        $29.30 /

        +0.73 (+2.56%)

        AFRM Affirm
        $70.60 /

        +0.81 (+1.16%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        NCLH Norwegian Cruise Line
        $30.53 /

        -0.08 (-0.26%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        IIVI II-VI
        $76.26 /

        +0.04 (+0.05%)

        GS Goldman Sachs
        $330.85 /

        -0.13 (-0.04%)

        CS Credit Suisse
        $10.64 /

        -0.305 (-2.79%)

        CCL Carnival
        $29.30 /

        +0.73 (+2.56%)

        AFRM Affirm
        $70.60 /

        +0.81 (+1.16%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        RCL Royal Caribbean
        $89.86 /

        +0.08 (+0.09%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        NCLH Norwegian Cruise Line
        $30.53 /

        -0.08 (-0.26%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        GS Goldman Sachs
        $330.85 /

        -0.13 (-0.04%)

        CS Credit Suisse
        $10.64 /

        -0.305 (-2.79%)

        CCL Carnival
        $29.30 /

        +0.73 (+2.56%)

        AFRM Affirm
        $70.60 /

        +0.81 (+1.16%)

        Periodicals
        Harley-Davidson nominates Ford CEO to join board, Bloomberg reports » 19:47
        04/11/21
        04/11
        19:47
        04/11/21
        19:47
        HOG

        Harley-Davidson

        $42.06 /

        +1.46 (+3.60%)

        , F

        Ford

        $12.51 /

        +0.005 (+0.04%)

        Harley-Davidson (HOG)…

        Harley-Davidson (HOG) nominated Ford Motor (F) Chief Executive Officer Jim Farley to join its board, the latest move by CEO Jochen Zeitz as he seeks to revive the struggling motorcycle maker and prepare it for an electric future, reported Bloomberg's Kristen Brown and Gabrielle Coppola. Reference Link

        ShowHide Related Items >><<
        HOG Harley-Davidson
        $42.06 /

        +1.46 (+3.60%)

        F Ford
        $12.51 /

        +0.005 (+0.04%)

        HOG Harley-Davidson
        $42.06 /

        +1.46 (+3.60%)

        04/09/21
        Fly Intel: Top five analyst upgrades
        04/09/21 Northcoast
        Harley-Davidson upgraded to Buy on 'robust' U.S. demand at Northcoast
        04/09/21 Northcoast
        Harley-Davidson upgraded to Buy from Neutral at Northcoast
        03/31/21 Baird
        Baird upgrades Harley-Davidson to Outperform as dealer survey improves
        F Ford
        $12.51 /

        +0.005 (+0.04%)

        04/05/21
        Fly Intel: Top five analyst initiations
        04/05/21 Wells Fargo
        Ford initiated with an Overweight at Wells Fargo
        03/29/21 Jefferies
        Ford price target raised to $16 from $14 at Jefferies
        03/19/21
        Fly Intel: Top five analyst upgrades
        HOG Harley-Davidson
        $42.06 /

        +1.46 (+3.60%)

        F Ford
        $12.51 /

        +0.005 (+0.04%)

        HOG Harley-Davidson
        $42.06 /

        +1.46 (+3.60%)

        F Ford
        $12.51 /

        +0.005 (+0.04%)

        HOG Harley-Davidson
        $42.06 /

        +1.46 (+3.60%)

        F Ford
        $12.51 /

        +0.005 (+0.04%)

        HOG Harley-Davidson
        $42.06 /

        +1.46 (+3.60%)

        F Ford
        $12.51 /

        +0.005 (+0.04%)

        Periodicals
        Google 'Project Bernanke' revealed in Texas antitrust case, WSJ reports » 19:36
        04/11/21
        04/11
        19:36
        04/11/21
        19:36
        GOOG

        Alphabet

        $2,285.38 /

        +20.38 (+0.90%)

        , GOOGL

        Alphabet Class A

        $2,270.31 /

        +20.25 (+0.90%)

        Google for years operated…

        Google for years operated a secret program that used data from past bids in the company's digital advertising exchange to allegedly give its own ad-buying system an advantage over competitors, report The Wall Street Journal's Jeff Horwitz and Keach Hagey, citing court documents filed in a Texas antitrust lawsuit. The program, known as "Project Bernanke," wasn't disclosed to publishers who sold ads through Google's ad-buying systems, note the authors. It generated hundreds of millions of dollars in revenue for the company annually, the documents show. In its lawsuit, Texas alleges that the project gave Google an unfair competitive advantage over rivals, adds the publication. Reference Link

        ShowHide Related Items >><<
        GOOGL Alphabet Class A
        $2,270.31 /

        +20.25 (+0.90%)

        GOOG Alphabet
        $2,285.38 /

        +20.38 (+0.90%)

        GOOG Alphabet
        $2,285.38 /

        +20.38 (+0.90%)

        04/05/21 Evercore ISI
        Alphabet assumed with an Outperform at Evercore ISI
        04/01/21 Morgan Stanley
        Microsoft making progress toward being 'Netflix of Gaming,' says Morgan Stanley
        03/31/21 Wolfe Research
        Alphabet initiated with an Outperform at Wolfe Research
        03/30/21
        Fly Intel: Top five analyst upgrades
        GOOGL Alphabet Class A
        $2,270.31 /

        +20.25 (+0.90%)

        04/09/21 Argus
        Alphabet price target raised to $2,500 from $2,400 at Argus
        GOOGL Alphabet Class A
        $2,270.31 /

        +20.25 (+0.90%)

        GOOG Alphabet
        $2,285.38 /

        +20.38 (+0.90%)

        GOOG Alphabet
        $2,285.38 /

        +20.38 (+0.90%)

        GOOG Alphabet
        $2,285.38 /

        +20.38 (+0.90%)

        GOOGL Alphabet Class A
        $2,270.31 /

        +20.25 (+0.90%)

        GOOG Alphabet
        $2,285.38 /

        +20.38 (+0.90%)

        Periodicals
        Supply-chain software provider Blue Yonder weighing IPO, WSJ reports » 19:33
        04/11/21
        04/11
        19:33
        04/11/21
        19:33
        SAP

        SAP

        $133.79 /

        +0.63 (+0.47%)

        , ORCL

        Oracle

        $75.58 /

        +0.29 (+0.39%)

        Blue Yonder is planning…

        Blue Yonder is planning to go public, the latest technology provider to look at a public stock offering as pandemic-driven upheaval in supply chains draws more interest to tools that help companies manage the flow of goods, reported The Wall Street Journal's Jennifer Smith. Blue Yonder said it has confidentially filed paperwork with the Securities and Exchange Commission for a proposed initial public offering, notes the author, adding that data research group Garner ranked Blue Yonder last year as the world's third-largest provider in the supply-chain-management software market, based on 2019 revenue, behind SAP SE (SAP) and Oracle (ORCL). Reference Link

        ShowHide Related Items >><<
        SAP SAP
        $133.79 /

        +0.63 (+0.47%)

        ORCL Oracle
        $75.58 /

        +0.29 (+0.39%)

        SAP SAP
        $133.79 /

        +0.63 (+0.47%)

        04/09/21 Societe Generale
        SAP price target lowered to EUR 136 from EUR 138 at Societe Generale
        03/25/21 Credit Suisse
        SAP assumed with an Outperform at Credit Suisse
        03/12/21 JMP Securities
        Domo price target raised to $89 from $80 at JMP Securities
        03/10/21 Craig-Hallum
        Talend go-shop 'could spark interest,' says Craig-Hallum
        ORCL Oracle
        $75.58 /

        +0.29 (+0.39%)

        04/09/21 Argus
        Alphabet price target raised to $2,500 from $2,400 at Argus
        04/07/21 UBS
        Database checks not showing growth acceleration for Oracle, says UBS
        03/31/21 Wedbush
        Oracle reinstated with a Neutral at Wedbush
        03/23/21 KeyBanc
        Box price target raised to $27 from $22 at KeyBanc
        SAP SAP
        $133.79 /

        +0.63 (+0.47%)

        ORCL Oracle
        $75.58 /

        +0.29 (+0.39%)

        SAP SAP
        $133.79 /

        +0.63 (+0.47%)

        ORCL Oracle
        $75.58 /

        +0.29 (+0.39%)

        SAP SAP
        $133.79 /

        +0.63 (+0.47%)

        ORCL Oracle
        $75.58 /

        +0.29 (+0.39%)

        SAP SAP
        $133.79 /

        +0.63 (+0.47%)

        ORCL Oracle
        $75.58 /

        +0.29 (+0.39%)

        Periodicals
        Ingersoll-Rand nearing $1.7B deal to sell golf cart business, Reuters reports » 19:29
        04/11/21
        04/11
        19:29
        04/11/21
        19:29
        IR

        Ingersoll-Rand

        $50.59 /

        +0.255 (+0.51%)

        Ingersoll-Rand is nearing…

        Ingersoll-Rand is nearing a deal to sell its golf cart business to Platinum Equity for around $1.7B, Reuters' Joshua Franklin, citing people familiar with the matter. The deal will separate Ingersoll Rand from a business it acquired in 1995 and is the latest in a series of divestitures that CEO Vicente Reynal has embarked on to pay down debt and streamline the company's portfolio, notes the author. Reference Link

        ShowHide Related Items >><<
        IR Ingersoll-Rand
        $50.59 /

        +0.255 (+0.51%)

        IR Ingersoll-Rand
        $50.59 /

        +0.255 (+0.51%)

        04/06/21 Barclays
        Ingersoll-Rand price target raised to $56 from $53 at Barclays
        02/24/21 Deutsche Bank
        Ingersoll-Rand price target raised to $50 from $47 at Deutsche Bank
        02/16/21 UBS
        Ingersoll-Rand's deal to sell HPS interest 'positive,' says UBS
        01/15/21 Jefferies
        Ingersoll-Rand price target raised to $53 from $45 at Jefferies
        IR Ingersoll-Rand
        $50.59 /

        +0.255 (+0.51%)

        • 17
          Jun
        Periodicals
        Apple agrees to testify before Senate on app store concerns, Reuters reports » 19:26
        04/11/21
        04/11
        19:26
        04/11/21
        19:26
        AAPL

        Apple

        $133.00 /

        +2.63 (+2.02%)

        A senior Apple executive…

        A senior Apple executive has agreed to testify before the Senate on competition issues related to mobile app stores, reported Reuters' Paresh Dave. The company said in a letter sent to senators, seen by Reuters, that Chief Compliance Officer Kyle Andeer will be available to testify at an April 21 hearing held by part of the Senate Judiciary Committee. Reference Link

        ShowHide Related Items >><<
        AAPL Apple
        $133.00 /

        +2.63 (+2.02%)

        AAPL Apple
        $133.00 /

        +2.63 (+2.02%)

        04/09/21 Citi
        Citi tells investors to focus on Apple's capital deployment, iPhone gains
        04/08/21 Piper Sandler
        Teen iPhone ownership continues to increase, says Piper Sandler
        04/06/21 Cowen
        Apple's News product a key growth pillar, says Cowen
        04/06/21 Morgan Stanley
        Morgan Stanley raises Services forecast for Apple, trims price target to $156
        AAPL Apple
        $133.00 /

        +2.63 (+2.02%)

        AAPL Apple
        $133.00 /

        +2.63 (+2.02%)

        AAPL Apple
        $133.00 /

        +2.63 (+2.02%)

        AAPL Apple
        $133.00 /

        +2.63 (+2.02%)

        On The Fly
        Box Office Battle: 'Godzilla vs. Kong' wins weekend with $13.4M » 19:22
        04/11/21
        04/11
        19:22
        04/11/21
        19:22
        T

        AT&T

        $30.04 /

        +0.04 (+0.13%)

        , CMCSA

        Comcast

        $53.55 /

        -0.79 (-1.45%)

        , CMCSK

        Comcast

        $58.00 /

        + (+0.00%)

        , SNE

        Sony

        /

        +

        , LGF.A

        Lionsgate

        $16.12 /

        +0.055 (+0.34%)

        , LGF.B

        Lionsgate

        $13.82 /

        +0.15 (+1.10%)

        , DIS

        Disney

        $187.81 /

        +0.485 (+0.26%)

        , VIACA

        ViacomCBS

        $46.95 /

        +0.48 (+1.03%)

        , VIAC

        ViacomCBS

        $41.85 /

        -0.43 (-1.02%)

        "Box Office Battle" is…

        ShowHide Related Items >><<
        VIACA ViacomCBS
        $46.95 /

        +0.48 (+1.03%)

        VIAC ViacomCBS
        $41.85 /

        -0.43 (-1.02%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        SNE Sony
        /

        +

        LGF.B Lionsgate
        $13.82 /

        +0.15 (+1.10%)

        LGF.A Lionsgate
        $16.12 /

        +0.055 (+0.34%)

        DIS Disney
        $187.81 /

        +0.485 (+0.26%)

        CMCSK Comcast
        $58.00 /

        + (+0.00%)

        CMCSA Comcast
        $53.55 /

        -0.79 (-1.45%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        03/10/21 RBC Capital
        Fortinet price target raised to $175 from $162 at RBC Capital
        03/10/21 DA Davidson
        Fortinet price target raised to $200 from $180 at DA Davidson
        03/10/21 BTIG
        Fortinet price target raised to $205 from $183 at BTIG
        03/05/21 JPMorgan
        JPMorgan sees AT&T rallying into analyst meeting, but not after
        CMCSA Comcast
        $53.55 /

        -0.79 (-1.45%)

        04/09/21 Citi
        Comcast price target raised to $62 from $59 at Citi
        03/23/21 Macquarie
        Disney 'realtive winner' from NFL rights deals, says Macquarie
        03/18/21 Credit Suisse
        Comcast price target raised to $67 from $61 at Credit Suisse
        03/16/21 Wells Fargo
        Wells starts Comcast at sell, says not good stock in current form
        CMCSK Comcast
        $58.00 /

        + (+0.00%)

        02/23/21 Credit Suisse
        SeaWorld price target raised to $52 from $34 at Credit Suisse
        10/07/20 Benchmark
        Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
        09/22/20 Benchmark
        Comcast price target raised to $60 from $54 at Benchmark
        09/16/20 Pivotal Research
        Comcast price target raised to $60 from $52 at Pivotal Research
        SNE Sony
        /

        +

        04/09/21 Benchmark
        Netflix deal for Sony films 'hardly transformative,' says Benchmark
        03/08/21 Macquarie
        Sony downgraded to Neutral from Outperform at Macquarie
        03/08/21 BofA
        BofA says buy AMD and Nvidia as Steam data points to GPU upgrade tailwinds
        01/12/21 Citi
        Sony PS5 sales to date 'steady but somewhat disappointing,' says Citi
        LGF.A Lionsgate
        $16.12 /

        +0.055 (+0.34%)

        02/08/21 Deutsche Bank
        Lionsgate price target raised to $16 from $12 at Deutsche Bank
        02/05/21 RBC Capital
        Lionsgate price target raised to $13 from $7 at RBC Capital
        01/28/21 Macquarie
        Lionsgate price target raised to $18 from $12 at Macquarie
        LGF.B Lionsgate
        $13.82 /

        +0.15 (+1.10%)

        11/02/20 Morgan Stanley
        Lionsgate assumed with an Equal Weight at Morgan Stanley
        09/02/20 Barrington
        Lionsgate price target raised to $14 from $10 at Barrington
        05/05/20 Canaccord
        Lionsgate price target lowered to $13 from $16 at Canaccord
        DIS Disney
        $187.81 /

        +0.485 (+0.26%)

        04/08/21 KeyBanc
        Netflix, Disney superior retention reinforces scale advantages, says KeyBanc
        03/29/21 Loop Capital
        ViacomCBS upgraded to Hold at Loop Capital after share price decline
        03/24/21 B. Riley
        Disney 'day-and-date' decision negative for exhibitors, says B. Riley
        VIACA ViacomCBS
        $46.95 /

        +0.48 (+1.03%)

        01/05/21 Gabelli
        ViacomCBS named a best idea for 2021 at Gabelli
        07/13/20
        Fly Intel: Top five analyst initiations
        07/13/20
        Fly Intel: Top five analyst downgrades
        VIAC ViacomCBS
        $41.85 /

        -0.43 (-1.02%)

        04/07/21 Wolfe Research
        Wolfe upgrades ViacomCBS to Outperform, sees 58% share upside
        04/07/21 Wolfe Research
        ViacomCBS upgraded to Outperform from Peer Perform at Wolfe Research
        03/30/21
        Fly Intel: Top five analyst upgrades
        03/30/21 Gabelli
        ViacomCBS upgraded to Buy from Hold at Gabelli
        VIACA ViacomCBS
        $46.95 /

        +0.48 (+1.03%)

        VIAC ViacomCBS
        $41.85 /

        -0.43 (-1.02%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        SNE Sony
        /

        +

        LGF.A Lionsgate
        $16.12 /

        +0.055 (+0.34%)

        DIS Disney
        $187.81 /

        +0.485 (+0.26%)

        CMCSA Comcast
        $53.55 /

        -0.79 (-1.45%)

        • 06
          Apr
        • 29
          Mar
        • 24
          Mar
        VIACA ViacomCBS
        $46.95 /

        +0.48 (+1.03%)

        VIAC ViacomCBS
        $41.85 /

        -0.43 (-1.02%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        SNE Sony
        /

        +

        LGF.A Lionsgate
        $16.12 /

        +0.055 (+0.34%)

        DIS Disney
        $187.81 /

        +0.485 (+0.26%)

        CMCSK Comcast
        $58.00 /

        + (+0.00%)

        CMCSA Comcast
        $53.55 /

        -0.79 (-1.45%)

        VIACA ViacomCBS
        $46.95 /

        +0.48 (+1.03%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        SNE Sony
        /

        +

        LGF.A Lionsgate
        $16.12 /

        +0.055 (+0.34%)

        CMCSA Comcast
        $53.55 /

        -0.79 (-1.45%)

        VIAC ViacomCBS
        $41.85 /

        -0.43 (-1.02%)

        T AT&T
        $30.04 /

        +0.04 (+0.13%)

        SNE Sony
        /

        +

        DIS Disney
        $187.81 /

        +0.485 (+0.26%)

        CMCSA Comcast
        $53.55 /

        -0.79 (-1.45%)

        Recommendations
        Volaris price target raised to $20.10 from $13 at Goldman Sachs » 19:13
        04/11/21
        04/11
        19:13
        04/11/21
        19:13
        VLRS

        Volaris

        $15.72 /

        +0.125 (+0.80%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim raised the firm's price target on Volaris to $20.10 from $13 and keeps a Buy rating on the shares. The analyst expects Volaris to continue to outperform its competitors "on the recovery." He expects Volaris' consolidated capacity in 2021 to be above 2019 levels as a result of weakened competition in Mexico and the company's expansion strategy to new routes "filling the gap left by competitors."

        ShowHide Related Items >><<
        VLRS Volaris
        $15.72 /

        +0.125 (+0.80%)

        VLRS Volaris
        $15.72 /

        +0.125 (+0.80%)

        03/05/21 Citi
        Volaris price target raised to $18.25 from $15.75 at Citi
        02/22/21 Barclays
        Volaris price target raised to $18 from $14 at Barclays
        02/22/21 Deutsche Bank
        Volaris upgraded to Buy from Hold at Deutsche Bank
        02/16/21 Citi
        Volaris price target raised to $15.75 from $13.25 at Citi
        VLRS Volaris
        $15.72 /

        +0.125 (+0.80%)

        • 09
          Dec
        Recommendations
        OMA price target lowered to $49 from $50 at Goldman Sachs » 19:11
        04/11/21
        04/11
        19:11
        04/11/21
        19:11
        OMAB

        OMA

        $53.34 /

        +0.46 (+0.87%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim lowered the firm's price target on OMA to $49 from $50 and keeps a Neutral rating on the shares. The analyst views the shares as fairly priced at current levels.

        ShowHide Related Items >><<
        OMAB OMA
        $53.34 /

        +0.46 (+0.87%)

        OMAB OMA
        $53.34 /

        +0.46 (+0.87%)

        03/24/21 BBVA
        OMA downgraded to Market Perform from Outperform at BBVA
        03/11/21 UBS
        OMA downgraded to Neutral from Buy at UBS
        12/14/20 Citi
        OMA downgraded to Neutral from Buy at Citi
        11/25/20 JPMorgan
        OMA assumed at Overweight from Neutral at JPMorgan
        Recommendations
        Gol Linhas price target lowered to $9.85 from $11.05 at Goldman Sachs » 19:10
        04/11/21
        04/11
        19:10
        04/11/21
        19:10
        GOL

        Gol Linhas

        $8.28 /

        -0.12 (-1.43%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim lowered the firm's price target on Gol Linhas to $9.85 from $11.05 and keeps a Buy rating on the shares following the stock's underperformance. Gol appears to have enough liquidity to cover its short-term debt, which could also be at least partially rolled over, Amorim tells investors in a research more. Moreover, if necessary, the capital markets conditions remain favorable, and Gol could seek additional funds to bolster its cash position, says the analyst.

        ShowHide Related Items >><<
        GOL Gol Linhas
        $8.28 /

        -0.12 (-1.43%)

        GOL Gol Linhas
        $8.28 /

        -0.12 (-1.43%)

        04/01/21 Itau BBA
        Gol Linhas initiated with a Market Perform at Itau BBA
        03/23/21 Morgan Stanley
        Gol Linhas downgraded to Underweight from Equal Weight at Morgan Stanley
        03/05/21 Deutsche Bank
        Gol Linhas upgraded to Buy after recent selloff at Deutsche Bank
        03/05/21 Deutsche Bank
        Gol Linhas upgraded to Buy from Hold at Deutsche Bank
        GOL Gol Linhas
        $8.28 /

        -0.12 (-1.43%)

        GOL Gol Linhas
        $8.28 /

        -0.12 (-1.43%)

        Downgrade
        GAP Airports downgraded to Neutral from Buy at Goldman Sachs » 19:08
        04/11/21
        04/11
        19:08
        04/11/21
        19:08
        PAC

        GAP Airports

        $109.66 /

        +0.105 (+0.10%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim downgraded GAP Airports to Neutral from Buy with a price target of $106, down from $120. The analyst sees a slower than previously expected recovery in traffic in the domestic market in Mexico and weaker traffic in Jamaican Airports. As such, he views the valuation as "tight" at current share levels.

        ShowHide Related Items >><<
        PAC GAP Airports
        $109.66 /

        +0.105 (+0.10%)

        PAC GAP Airports
        $109.66 /

        +0.105 (+0.10%)

        03/24/21 BBVA
        GAP Airports downgraded to Market Perform from Outperform at BBVA
        03/11/21 UBS
        GAP Airports downgraded to Sell from Neutral at UBS
        02/01/21 Citi
        GAP Airports price target lowered to $116 from $122 at Citi
        12/23/20 Citi
        Airline demand in early 2021 'looks soft,' says Citi
        PAC GAP Airports
        $109.66 /

        +0.105 (+0.10%)

        Hot Stocks
        DiaSorin SpA to acquire Luminex for $37 per share » 19:06
        04/11/21
        04/11
        19:06
        04/11/21
        19:06
        LMNX

        Luminex

        $32.92 /

        +0.64 (+1.98%)

        , DSRLF

        DiaSorin SpA

        $165.82 /

        +0.8151 (+0.49%)

        DiaSorin SpA (DSRLF)…

        DiaSorin SpA (DSRLF) announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex (LMNX) for a price of $37 per share in an all-cash transaction. This corresponds to a total equity value of approximately $1.8B on a fully diluted basis and an enterprise value of approximately $1.8B. Following the acquisition, the combined entity will have combined 2020 revenues of approximately EUR 1.25B, adjusted EBITDA of approximately EUR 472M, and positive Net Financial Position of approximately EUR 335M. The transaction is expected to close within the third quarter of 2021 and is subject to Luminex shareholder approval and to other customary closing conditions, including the satisfaction of antitrust and CFIUS regulatory requirements. The transaction will be immediately accretive to DiaSorin's earnings per share following closing of the transaction and will generate an attractive return on invested capital profile. The combination is also anticipated to result in cost synergies of approximately $55M within 3 years after closing.

        ShowHide Related Items >><<
        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        02/18/21 Piper Sandler
        Luminex shares are undervalued, says Piper Sandler
        12/17/20 BTIG
        Illumina upgraded to Buy from Neutral at BTIG
        11/09/20 Piper Sandler
        Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
        11/06/20 Piper Sandler
        Luminex's new product launches can drive long-term growth, says Piper Sandler
        DSRLF DiaSorin SpA
        $165.82 /

        +0.8151 (+0.49%)

        03/24/21 Berenberg
        DiaSorin SpA price target lowered to EUR 150 from EUR 180 at Berenberg
        03/18/21 Morgan Stanley
        DiaSorin SpA downgraded to Underweight from Equal Weight at Morgan Stanley
        12/10/20 Exane BNP Paribas
        DiaSorin SpA price target raised to EUR 145 from EUR 135 at Exane BNP Paribas
        12/10/20 Kepler Cheuvreux
        DiaSorin SpA upgraded to Buy from Hold at Kepler Cheuvreux
        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        LMNX Luminex
        $32.92 /

        +0.64 (+1.98%)

        Upgrade
        Copa Holdings upgraded to Buy from Neutral at Goldman Sachs » 19:04
        04/11/21
        04/11
        19:04
        04/11/21
        19:04
        CPA

        Copa Holdings

        $80.56 /

        -0.68 (-0.84%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim upgraded Copa Holdings to Buy from Neutral with a price target of $100, up from $73. Copa company remains a "high-quality name" in Latin America Transportation with a "strong" balance sheet and strategic positioning due to its hub-based model with limited competition, Amorim tells investors in a research note. Further, the company's main competitors in Latin America are all undergoing restructuring processes, the analyst adds. Moreover, as the vaccination roll-out advances in Latin America and international demand recovers, Copa's 2023 EBITDA should be only 3% below 2019 levels, says Amorim.

        ShowHide Related Items >><<
        CPA Copa Holdings
        $80.56 /

        -0.68 (-0.84%)

        CPA Copa Holdings
        $80.56 /

        -0.68 (-0.84%)

        03/22/21 JPMorgan
        Copa downgraded to Underweight on cautious sector view at JPMorgan
        03/22/21 JPMorgan
        Copa Holdings downgraded to Underweight from Neutral at JPMorgan
        03/05/21 Wolfe Research
        Wolfe upgrades Airlines sector to neutral on 'powerful market forces'
        01/28/21 Deutsche Bank
        Copa downgraded to Hold on slowing recovery at Deutsche Bank
        CPA Copa Holdings
        $80.56 /

        -0.68 (-0.84%)

        CPA Copa Holdings
        $80.56 /

        -0.68 (-0.84%)

        Downgrade
        Azul downgraded to Neutral from Buy at Goldman Sachs » 19:02
        04/11/21
        04/11
        19:02
        04/11/21
        19:02
        AZUL

        Azul

        $20.82 /

        -0.86 (-3.97%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim downgraded Azul to Neutral from Buy with a price target of $22.20, up from $21.60. The analyst cites valuation for the downgrade. The shares are fully pricing in a "steep recovery" in demand for upcoming years, Amorim tells investors in a research note.

        ShowHide Related Items >><<
        AZUL Azul
        $20.82 /

        -0.86 (-3.97%)

        AZUL Azul
        $20.82 /

        -0.86 (-3.97%)

        03/23/21 Morgan Stanley
        Azul downgraded to Underweight from Equal Weight at Morgan Stanley
        03/22/21 JPMorgan
        Azul downgraded to Underweight on cautious sector view at JPMorgan
        03/22/21 JPMorgan
        Azul downgraded to Underweight from Neutral at JPMorgan
        03/05/21 Deutsche Bank
        Azul upgraded to Buy after recent selloff at Deutsche Bank
        Downgrade
        Asur downgraded to Sell from Neutral at Goldman Sachs » 19:00
        04/11/21
        04/11
        19:00
        04/11/21
        19:00
        ASR

        Asur

        $183.91 /

        -3.26 (-1.74%)

        Goldman Sachs analyst…

        Goldman Sachs analyst Bruno Amorim downgraded Asur to Sell from Neutral with a price target of $165, up from $135. Within the Mexican airports space, Asur's share price has recovered the most versus pre-pandemic levels, Amorim tells investors in a research note. The analyst views the current valuation as expensive and says that under a scenario of traffic downturn, the company would be less protected versus peers.

        ShowHide Related Items >><<
        ASR Asur
        $183.91 /

        -3.26 (-1.74%)

        ASR Asur
        $183.91 /

        -3.26 (-1.74%)

        03/24/21 BBVA
        Asur upgraded to Outperform from Underperform at BBVA
        03/11/21 UBS
        Asur downgraded to Neutral from Buy at UBS
        12/23/20 Citi
        Airline demand in early 2021 'looks soft,' says Citi
        12/04/20 Scotiabank
        Asur downgraded to Underperform from Sector Perform at Scotiabank
        ASR Asur
        $183.91 /

        -3.26 (-1.74%)

        Periodicals
        Microsoft in talks to buy Nuance for about $56 per share, Bloomberg says » 18:43
        04/11/21
        04/11
        18:43
        04/11/21
        18:43
        NUAN

        Nuance

        $45.59 /

        +0.38 (+0.84%)

        , MSFT

        Microsoft

        $255.73 /

        +2.37 (+0.94%)

        Microsoft (MSFT) is in…

        Microsoft (MSFT) is in advanced talks to buy Nuance Communications (NUAN) in a deal with an equity value of about $16B, or about $56 per share, according to Bloomberg's Liana Baker, Kiel Porter, and Dina Bass, citing people familiar with the matter. Microsoft and Nuance have collaborated since 2019, noted the report, which added that an agreement could be announced as soon as this week. Nuance shares closed trading Friday, April 9, at $45.58 per share. Reference Link

        ShowHide Related Items >><<
        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        03/10/21 Wedbush
        Nuance added to Best Ideas List at Wedbush
        03/08/21 Morgan Stanley
        Software industry rating raised to Attractive from In-Line at Morgan Stanley
        02/09/21 Craig-Hallum
        Nuance price target raised to $58 from $41 at Craig-Hallum
        01/21/21 Barclays
        Nuance price target raised to $60 from $47 at Barclays
        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        04/09/21 BTIG
        Okta upgraded to Buy from Neutral at BTIG
        04/08/21 Morgan Stanley
        CIO survey provides strong data points for Microsoft, says Morgan Stanley
        04/05/21
        Fly Intel: Top five analyst initiations
        04/05/21 Credit Suisse
        Microsoft assumed with an Outperform at Credit Suisse
        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        NUAN Nuance
        $45.59 /

        +0.38 (+0.84%)

        MSFT Microsoft
        $255.73 /

        +2.37 (+0.94%)

        Hot Stocks
        Checkmate presents new clinical trial translational data with Vidutolimod » 18:24
        04/11/21
        04/11
        18:24
        04/11/21
        18:24
        CMPI

        Checkmate Pharmaceuticals

        $10.52 /

        +0.14 (+1.35%)

        Checkmate Pharmaceuticals…

        Checkmate Pharmaceuticals announced the presentation of new translational data from Checkmate's Phase 1b trial of vidutolimod in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma. Key highlights from these clinical data include: 93% of patients had progressive disease as their last response assessment on prior PD-1 blockade therapy, 42% had an elevated LDH, and the median sum of the target lesions longest diameter was 6.7 cm, indicating advanced disease; Response rates to vidutolimod in combination with pembrolizumab were similar across baseline patient characteristics including BRAF mutation, LDH level, number of prior systemic cancer treatments, best response to prior PD-1 blockade therapy, and prior ipilimumab; Responders and non-responders were not distinguished by baseline tumor characteristics including PD-L1 CPS, IFNg transcriptional signature, CD8+ T cells, or nonsynonymous mutations; All patients showed the expected rapid induction of anti-Qb antibodies to the virus-like particle, which facilitate the pharmacodynamic response to vidutolimod, and the antibody titers were not associated with clinical response; Clinical activity of vidutolimod in combination with pembrolizumab was associated with serum CXCL10 induction magnitude, induction of an inflammatory gene expression profile, and CD8+ T cells in injected and noninjected tumors.

        ShowHide Related Items >><<
        CMPI Checkmate Pharmaceuticals
        $10.52 /

        +0.14 (+1.35%)

        CMPI Checkmate Pharmaceuticals
        $10.52 /

        +0.14 (+1.35%)

        03/19/21 Jefferies
        Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
        09/01/20 Jefferies
        Checkmate Pharmaceuticals initiated with a Buy at Jefferies
        09/01/20 BofA
        BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
        09/01/20 BofA
        Checkmate Pharmaceuticals initiated with a Neutral at BofA
        CMPI Checkmate Pharmaceuticals
        $10.52 /

        +0.14 (+1.35%)

        • 07
          Aug
        Hot Stocks
        BeiGene presents clinical data on Sitravatinib, Tislelizumab combo » 18:22
        04/11/21
        04/11
        18:22
        04/11/21
        18:22
        BGNE

        BeiGene

        $308.27 /

        -5.8 (-1.85%)

        , MRTX

        Mirati Therapeutics

        $170.25 /

        +3.12 (+1.87%)

        BeiGene (BGNE) announced…

        BeiGene (BGNE) announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics (MRTX), were presented in two oral presentations at the American Association for Cancer Research Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial, in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patients with advanced platinum-resistant ovarian cancer. BeiGene has an exclusive collaboration and license agreement with Mirati for the development, manufacturing and commercialization of sitravatinib in Asia - excluding Japan, Australia, and New Zealand. This open-label, multicohort, Phase 1b trial was designed to evaluate safety/tolerability and preliminary antitumor activity of sitravatinib in combination with tislelizumab in advanced solid tumors. The primary endpoint of the trial was safety/tolerability of the combination; key secondary endpoints include investigator-assessed objective response rate, disease control rate, and progression-free survival per RECIST v1.1; overall survival was also assessed. At the time of data cutoff on October 13, 2020, a total of 25 patients with unresectable or metastatic melanoma who were refractory or resistant to anti-PD-1/L1 antibodies and had not received other prior immunotherapy had been enrolled in cohort G of the Phase 1b trial, including 12 with cutaneous subtype, seven with acral subtype, and four with mucosal subtype. At the time of data cutoff, 16 patients remained on study treatment. With a median follow-up time of 5.5 months, results included: All 25 patients experienced at least one treatment-emergent adverse event of any grade; Twelve patients experienced at least one Grade greater than or equal to 3 TEAE; One patient experienced a serious TEAE of anal abscess, associated with sitravatinib; Treatment discontinuation due to TEAEs occurred in two patients, with one discontinuing tislelizumab due to vaginal hemorrhage and the other sitravatinib due to increased BCK; Dose interruptions and reductions of sitravatinib occurred in 18 patients and 13 patients, respectively; All 25 patients were evaluable for efficacy and the confirmed ORR was 24%, including six partial responses, and the disease control rate was 88%; and the media duration of response was not reached, and the investigator-assessed median PFS was 6.7 months. Results in Patients with Advanced PROC include: At the time of data cutoff on October 13, 2020, a total of 60 patients with recurrent PROC who had no prior exposure to anti-PD-1/L1 antibodies had been enrolled in cohort E of the Phase 1b trial and 13 of them remained on study treatment. These patients received a median of four prior regimens. With a median follow-up time of six months, results included: Fifty-eight patients experienced at least one TEAE of any grade; Forty-one patients experienced at least one Grade greater than or equal to 3 TEAE; Forty-two patients experienced at least one serious TEAE; Treatment discontinuation due to TEAEs occurred in 23 patients, with nine patients discontinuing tislelizumab and 14 sitravatinib; Dose interruptions and reductions of sitravatinib occurred in 50 patients and 30 patients, respectively, and dose interruption of tislelizumab occurred in one patient; Four fatal TEAEs were reported, with none considered related to study treatment; Among the 53 patients who were evaluable for efficacy, the confirmed ORR was 26%; The median DoR was 4.7 months; and The median PFS and OS was 4.1 months and 12.9 months, respectively.

        ShowHide Related Items >><<
        MRTX Mirati Therapeutics
        $170.25 /

        +3.12 (+1.87%)

        BGNE BeiGene
        $308.27 /

        -5.8 (-1.85%)

        BGNE BeiGene
        $308.27 /

        -5.8 (-1.85%)

        03/16/21 HSBC
        BeiGene price target raised to $385 from $296 at HSBC
        03/08/21 China Renaissance
        BeiGene initiated with a Buy at China Renaissance
        03/04/21 Goldman Sachs
        Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
        03/01/21
        Fly Intel: Top five analyst downgrades
        MRTX Mirati Therapeutics
        $170.25 /

        +3.12 (+1.87%)

        03/01/21 Oppenheimer
        Mirati Therapeutics price target lowered to $255 from $260 at Oppenheimer
        01/15/21 H.C. Wainwright
        Mirati Therapeutics price target lowered to $257 from $265 at H.C. Wainwright
        12/08/20 JMP Securities
        Mirati Therapeutics initiated with a Market Perform at JMP Securities
        11/17/20 BofA
        Mirati Therapeutics downgraded to Underperform from Neutral at BofA
        MRTX Mirati Therapeutics
        $170.25 /

        +3.12 (+1.87%)

        BGNE BeiGene
        $308.27 /

        -5.8 (-1.85%)

        • 02
          Dec
        • 28
          Oct
        MRTX Mirati Therapeutics
        $170.25 /

        +3.12 (+1.87%)

        Hot Stocks
        Lyra Therapeutics presents full data set from LANTERN Phase 2 study » 18:14
        04/11/21
        04/11
        18:14
        04/11/21
        18:14
        LYRA

        Lyra Therapeutics

        $11.15 /

        -0.15 (-1.33%)

        Lyra Therapeutics…

        Lyra Therapeutics presented data from its Phase 2 LANTERN study of LYR-210, the company's lead long-acting product candidate for chronic rhinosinusitis, at the Combined Otolaryngology Spring Meetings 2021. LYR-210 is an investigational product candidate designed to be administered in-office and to deliver a sustained release therapeutic for up to six months at difficult-to-access nasal inflammation sites, as a non-invasive alternative to surgery for patients who have failed medical management. Lyra reported positive topline data from the LANTERN study in December 2020. The COSM oral presentation, titled Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study, contains the full 24-week data set from the company's Phase 2 clinical trial of LYR-210. Previously unpublished data included: improvement from baseline in bilateral ethmoid Zinreich scores by magnetic resonance imaging; symptom improvement in both polyp and non-polyp patients; and the need for and use of rescue medication during the trial. In Polyp vs Non-Polyp patients, symptom improvement was observed in both polyp and non-polyp patients, with 100% of patients at the 7500microgram dose in each group achieving the minimal clinically important difference of 8.9 points for SNOT-22 total score by week 24, with a single administration of LYR-210. In the LANTERN study, subjects underwent paranasal sinus MRI at baseline as well as at the end of treatment. LYR-210 achieved improvement in bilateral ethmoid Zinreich scores at week 24 in a dose-dependent manner, providing evidence of disease modification, with the 7500microgram dose achieving significant improvement compared to control between the two timepoints. Only 1 patient in the 7500microgram group and 2 patients in the 2500microgram group required a rescue treatment compared to 7 patients in the control group over the 24-week treatment period. The first incidence of rescue treatment in the control group occurred at week 2, while the only patient to require rescue treatment in the 7500microgram group did not require rescue treatment until after week 18. As such, LYR-210 reduced the need for rescue treatment. The need for rescue treatment in the LANTERN study was determined by the treating physician. Separately, Lyra has shared an analysis of the LANTERN study focused on a composite of three of the cardinal symptoms of CRS. Lyra announced an analysis of a composite score of three cardinal symptoms of CRS, which includes nasal blockage, nasal discharge and facial pain, which are the most prevalent symptoms for surgically naive CRS patients both with and without nasal polyps. With a single administration, LYR-210 achieved statistically significant improvement in the 3CS composite score compared to control at week 24 and at earlier timepoints.

        ShowHide Related Items >><<
        LYRA Lyra Therapeutics
        $11.15 /

        -0.15 (-1.33%)

        LYRA Lyra Therapeutics
        $11.15 /

        -0.15 (-1.33%)

        12/07/20 BofA
        Lyra Therapeutics price target raised to $26 from $19 at BofA
        05/26/20 BTIG
        Lyra Therapeutics initiated with a Buy at BTIG
        05/26/20 Jefferies
        Jefferies starts Lyra Therapeutics at Buy with $24 price target
        05/26/20 BofA
        BofA starts Lyra Therapeutics at Buy with $21 price target
        LYRA Lyra Therapeutics
        $11.15 /

        -0.15 (-1.33%)

        • 01
          May
        LYRA Lyra Therapeutics
        $11.15 /

        -0.15 (-1.33%)

        Hot Stocks
        Blueprint presents data from registrational PATHFINDER trial of AYVAKIT » 18:09
        04/11/21
        04/11
        18:09
        04/11/21
        18:09
        BPMC

        Blueprint Medicines

        $94.14 /

        +0.25 (+0.27%)

        Blueprint Medicines…

        Blueprint Medicines announced that multiple presentations across the company's leading systemic mastocytosis program were reported at the virtual American Association for Cancer Research Annual Meeting 2021. The presentations focused on registrational PATHFINDER trial data of AYVAKIT in advanced SM, PIONEER Part 1 data highlighting the impact of AYVAKIT on skin manifestations of SM, and Phase 1 trial data for BLU-263, a next-generation KIT D816V inhibitor. Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in non-advanced SM and other mast cell disorders. In a pre-specified interim analysis from the PATHFINDER trial, 32 patients who primarily received a starting dose of 200 mg once daily were evaluable for response, as of a data cutoff date of June 23, 2020. Combined with Phase 1 EXPLORER trial results, these data support Blueprint Medicines' marketing applications in advanced SM under review in the U.S. and Europe. Overall, 75 percent of patients had a confirmed response, which was defined as complete remission with full or partial recovery of peripheral blood counts, partial remission or clinical improvement. The median time to response was two months, and all responses were ongoing at a median follow-up of 10.4 months. The CRh rate was 19 percent, with a median time to CRh of 5.6 months. These results show that responses deepened over time at a rate consistent with the EXPLORER trial. The company said that AYVAKIT led to robust and durable benefits across a number of additional clinical activity measures. In new patient-reported outcomes data, AYVAKIT showed a statistically significant reduction in total symptom score after 40 weeks, as measured by the Advanced Systemic Mastocytosis Symptom Assessment Form. Treatment with AYVAKIT resulted in robust improvements in patient-reported quality of life, based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Across multiple measures of mast cell burden, AYVAKIT showed profound reductions in serum tryptase, bone marrow mast cells, KIT D816V allele burden and spleen volume. Consistent with previously disclosed data, AYVAKIT was generally well-tolerated in 62 patients enrolled in the PATHFINDER trial, and most adverse events were reported as Grade 1 or 2. The most common AEs were peripheral edema, periorbital edema, thrombocytopenia, anemia, neutropenia, diarrhea, nausea, vomiting and fatigue. Three patients discontinued AYVAKIT due to treatment-related AEs, and most patients have remained on treatment as of the data cutoff date. In non-advanced SM, skin symptoms frequently persist and can severely impact quality of life. To assess the effects of AYVAKIT on mast cell burden in skin lesions, skin biopsies were obtained at baseline and week 12 in Part 1 of the PIONEER trial. Immunohistochemistry tests were performed to determine the proportion of aberrant mast cells in skin tissue, based on expression of CD25, CD30 and other transmembrane receptors observed in SM. Skin lesional tissue at baseline had more CD30-positive than CD25-positive mast cells. Following 12 weeks of treatment, AYVAKIT significantly reduced the proportion of aberrant CD30-positive mast cells in skin lesions compared to placebo, as of a data cutoff date of December 4, 2020. These data expand on previously reported results showing the impact of AYVAKIT on skin manifestations of SM, and suggest that CD30 may be an important biomarker of aberrant mast cells in SM-related skin lesions. A placebo-controlled, Phase 1 trial evaluated the safety, tolerability and pharmacokinetics of BLU-263 in healthy volunteers. This AACR presentation reported on single ascending dose cohorts and multiple ascending dose cohorts, as of a data cutoff date of November 9, 2020. BLU-263 was well-tolerated across all doses studied, and all AEs were reported as Grade 1. Pharmacokinetic data showed dose-dependent increases in systemic exposure of BLU-263, with the half-life of BLU-263 supporting once-daily dosing. Based on these results, the company plans to evaluate BLU-263 at doses ranging from 25 to 100 mg once daily in Part 1 of the Phase 2/3 HARBOR trial in patients with non-advanced SM, which the company plans to initiate in mid-2021.

        ShowHide Related Items >><<
        BPMC Blueprint Medicines
        $94.14 /

        +0.25 (+0.27%)

        BPMC Blueprint Medicines
        $94.14 /

        +0.25 (+0.27%)

        04/09/21 Piper Sandler
        AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
        03/30/21 Credit Suisse
        Blueprint Medicines initiated with a Neutral at Credit Suisse
        03/30/21 Credit Suisse
        Blueprint Medicines initiated with a Neutral at Credit Suisse
        02/18/21 Barclays
        Blueprint Medicines price target raised to $95 from $90 at Barclays
        BPMC Blueprint Medicines
        $94.14 /

        +0.25 (+0.27%)

        Get Full Fly Access

        Breaking market intelligence sent straight to you
        Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
        Up-to-date information on important industry events
        Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
        News focused on the companies in your portfolio
        Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.